

Haematologica  
HAEMATOL/2020/249995  
Version 2

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome

Alana Vicente, Bhavisha A. Patel, Fernanda Gutierrez-Rodrigues, Emma Groarke, Valentina Giudice, Jennifer Lotter, Xingmin Feng, Sachiko Kajigaya, Barbara Weinstein, Evette Barranta, Matthew J. Olnes, Ankur R. Parikh, Maher Albitar, Colin O. Wu, Ruba Shalhoub, Katherine R. Calvo, Danielle M. Townsley, Phillip Scheinberg, Cynthia E. Dunbar, Neal S. Young, and Thomas Winkler

Disclosures: Eltrombopag was provided by GlaxoSmithKline and Novartis under a Clinical Trials Agreement with NHLBI. NSY and CED receive research funding from Novartis for additional experimental laboratory studies. DT is currently an employee of AstraZeneca, but has no involvement with the development of eltrombopag. TW is currently an employee of Agios, but has no involvement with the development of eltrombopag. AV is currently an employee of Pfizer, but has no involvement with the development of eltrombopag.

Contributions: Contributions: TW, D.T, P.S, C.E.D and N.S.Y designed studies; A.V, F.G.R, X.F, S.K, T.W, and D.T performed laboratory studies and clinical analyses; T.W, D.T, B.P, E.M.G, J.L, M.J.O, A.R.P, E.B, B.W, C.E.D, and N.S.Y provided clinical care; K.R.C provided pathologic interpretations; A.V, R.S, and C.O.W performed statistical analyses; M.A performed NGS analysis; A.V, B.V, F.G.R, T.W, C.E.D, and N.S.Y wrote and edited the manuscript